• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » TMS for the treatment of auditory hallucinations

TMS for the treatment of auditory hallucinations

May 1, 2007
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
James Ellison, MD, MPH

In the February issue of TCPR, we reported a recent FDA panel’s opinion that rTMS (repetitive transcranial magnetic stimulation) was relatively ineffective for treatment-resistant depression. The type of rTMS that has been tested for depression generally involves 10 Hz (ten pulses per second). But when the pulse of magnetic coils is slowed down to only 1 Hz, this reduces neuronal excitability, temporarily “stunning” those neurons subjected to the magnetic field. Researchers have been using this property to try to turn off the parts of the brain responsible for auditory hallucinations in schizophrenic patients. In a recent meta-analysis of such studies, the authors reviewed 10 TMS controlled trials (with sham-TMS as the control), and reported a robust average effect size of 0.88 (Aleman A et al., J Clin Psychiatry 2007;68:416-421). In the largest of the studies they reviewed, the anti-hallucination effect lasted about five months.

TCPR’s Take: This is potentially exciting stuff, but as is always the case with research, the devil is in the details. Most of these studies use specially created auditory hallucination scales to demonstrate a benefit of rTMS. These scales yield “hallucination scores” that decrease significantly with treatment, and are great for statistical testing, but not so helpful for clinicians trying to divine the applicability of the results to their patients. In fact, this meta-analysis found that while slow rTMS appears to decrease AH, it does not improve overall ratings of positive symptoms, making it debatable how useful this expensive treatment is likely to be forour patients.

General Psychiatry
KEYWORDS brain_devices
    www.thecarlatreport.com
    Issue Date: May 1, 2007
    SUBSCRIBE NOW
    Table Of Contents
    Medications for Dementia: An Update
    Normal Forgetfulness vs. Pre-Dementia: How to Distinguish Them
    Agitation and Depression in Older Patients
    Antidepressants shown ineffective for bipolar depression
    FDA orders consumer medication guides for stimulants
    The molecular mechanism of antipsychotic- induced weight gain is found
    TMS for the treatment of auditory hallucinations
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.